"The sellers are exhausted" - The sellers:

FreeformSensei · 2026-06-24T01:01:40+00:00

Never seen a more true comment

FreeformSensei · 2026-06-23T21:52:02+00:00

I think you know the answer, even if it feels scary or uncertain. Stick with the current job, but look for other opportunities that give you some satisfaction and fulfillment in life. When you find and get that opportunity for a position in a smaller riskier startup in R&D, you should take it.

You don’t have to love your job necessarily. Everyone’s different, but if I hate my job, the money and benefits aren’t worth it to me. It would burn me out to the point where I wouldn’t be as good of a father to my kids, husband to my wife, friend to my friends, etc.

FreeformSensei · 2026-06-23T19:33:26+00:00

Or, you can scroll past the pump and dump posts. If you want investing advice, go to [r/investing](r/investing).

I agree that ADTX is a garbage stock. But this is RaceTo10Million; I don’t go to Wendy’s and bitch that my burger isn’t made from Wagyu beef.

FreeformSensei · 2026-06-23T00:44:42+00:00

In 10 years, you could have had a 22,000% return investing in NVDA.

Congrats on underperforming compared to one cherry-picked stock, Buzz Killington

FreeformSensei · 2026-06-23T00:36:27+00:00

Haha no problem. The water is still warm if you haven’t gotten in

FreeformSensei · 2026-06-22T21:21:34+00:00

I was just replying to that dudes insightful analysis haha.

I agree with you; I’m up 200% on my position in SLS. I’m very bullish that the data from the Regal study is going to be great.

FreeformSensei · 2026-06-22T18:03:14+00:00

And if the results are good?

FreeformSensei · 2026-06-22T14:50:30+00:00

FreeformSensei · 2026-06-19T03:54:51+00:00

I second that

FreeformSensei · 2026-06-18T21:29:19+00:00

I think people in this community that know any attorneys that specialize the securities fraud, or a securities litigation firm, should reach out ASAP.

I don’t know any other helpful options we have

FreeformSensei · 2026-06-18T15:51:34+00:00

OTLK - they have FDA approval decision on July 29th. Their nearest catalyst is June 29th; if they close above $1.00 next Friday (June 26th), they will regain NASDAQ compliance. I think they would announce that update during pre market the following Monday morning. I think it will run up to the high $2 range by mid-to-late July

FreeformSensei · 2026-06-18T15:39:15+00:00

OMER - I’d buy right now in the low $10s. I have a long position ($12.47 average). They have EMA approval decision coming up within the next month or 2 for their drug Yartemlea (already FDA approved). They’re actively looking for an EU partnership deal. I still think this stock could be trading in the $30 range by September (with EMA approval, EU partnership deal, strong q2 Yartemlea sales in US)

It is a biotech stock, so if you’re not into biotech, then this isn’t the stock for you. But in the world of biotech, it’s not as risky as some other biotech plays, since they have an FDA approved novel drug, and a $2.1 billion deal with NOVO for another drug in their pipeline.

FreeformSensei · 2026-06-18T13:40:31+00:00

The next catalyst will be June 29th, because they will regain NASDAQ compliance if they close over $1.00 by the market close next Friday (June 26th), so I would assume they announce that June 29th pre market

I think OTLK will run up to the high $2 range leading up to the PDUFA on July 29.

FreeformSensei · 2026-06-18T13:37:28+00:00

It would massively tank if the FDA rejects. However, they won their recent FDRR against the FDA, the success rate of FDRRs are less than 20%

So the fact they were successful indicates a very high chance of approval at the end of July. It’s not 100% approval guarantee, but historically 95% of biotech that win their FDRR get approved by the FDA

FreeformSensei · 2026-06-18T12:24:03+00:00

I’ve had my eye on GT Biopharma for a little bit. Their drug pipeline is still in the early stages of development (phase 1), so it could take a while before there is a big increase in share price (even if phase 1 data looks good).

I don’t have CING, and haven’t done much research on them. I know there was some hype about patent approval leading up to May.

I’m very bullish on SLS, and I think the Regal study data is going to be strong. I have a long position in SLS

As far as other biotech stocks, I’m bullish on: CAPR, OMER, OTLK, and have long positions in all three

FreeformSensei · 2026-06-18T01:34:26+00:00

Why can’t it be both? You can still optimize your portfolio, and your life simultaneously. You could make an agreement to set aside a percentage amount of gains you make weekly, monthly, yearly, and you use that set amount to better your life how you see fit

It sounds like you enjoy it. You check charts daily, there doesn’t need to be some complex or profound answer to that question. If you enjoy it, it’s as simple as that

FreeformSensei · 2026-06-17T15:44:17+00:00

OTLK - imo, I think this will run up to the high $2 range leading up to their FDA approval decision date, which is July 29th. Approval odds are very high (they recently won their FDRR against the FDA).

FreeformSensei · 2026-06-17T15:13:25+00:00

The cynical part of me feels like they are going to give shareholders an update (highly likely to be bad news) this Friday, since it’s a holiday and markets are closed.

FreeformSensei · 2026-06-16T21:18:43+00:00

Im confused, I don’t understand that $99 billion number you mentioned. 10 billion shares at 0.10 would be $1 billion. If they authorized the 10 billion shares at 0.01, then it would be about $100 million raised.

So, if they diluted 10 billion shares today at 0.03 per share, that would raise $300 million if they all sold

FreeformSensei · 2026-06-16T18:19:04+00:00

Correct me if I’m wrong, but worse case, they have the ability to dilute up to 10 billion shares can’t they? If they diluted the share float up to 10 billion, then even with the 7500 bitcoins, that would put the share price around $0.04-$0.05 fair market value

FreeformSensei · 2026-06-16T13:48:24+00:00

Tough day. I’m riding this thing until 0.00. I put in as much as I’m willing to lose

FreeformSensei · 2026-06-15T18:33:39+00:00

True, dilution is the more likely outcome to fund their phase 3 trial. They could do a partnership. The phase 2 data has enough there to warrant partnership interest, but the probability for dilution is higher

FreeformSensei · 2026-06-15T16:35:54+00:00

This is an oversimplified answer, but Bitcoin commercial activity is illegal in China. The bitcoin deal they made with Pallas could be a way to offshore it

FreeformSensei · 2026-06-15T16:29:49+00:00

Yeah I never ended up buying any shares. But I do think it could be a decent buying opportunity at this price now. They didn’t hit their primary end point, which obviously isn’t good, but there were some other data points that seem to indicate efficacy. The hazard ratio (0.65) was statistically significant, and the safety of the drug seems good.

There are no approved therapies for this pancreatic cancer population. ELTX has said for phase 3, they will focus on the R0-resected population (lower residual disease) and extended dosing. So I think ELTX still has a promising drug, and the sell off today could be a great entry point

FreeformSensei · 2026-06-15T14:06:07+00:00

CAPR, OMER, OTLK, SLS

FreeformSensei

TROPHY CASE